TORRANCE, Calif., Aug. 28, 2019 /PRNewswire/ -- Emmaus Life
Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease
treatment, announced today the addition of Oncology Supply, a part
of Amerisource Bergen, as a distributor of its signature product,
Endari® (L-glutamine oral powder).
"It has been our goal and stated mission to ensure broad
availability of Endari for sickle cell disease patients where
it is medically appropriate," says Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief
Executive Officer of Emmaus. "We look forward to the added patient
access and community expertise Oncology Supply can provide. This
new partnership builds on the strong momentum evidenced by our
recently announced second quarter financial results, including a
128% increase in net revenues year over year."
"Endari is the only product in over 20 years approved by the FDA
for treating sickle cell disease. Many SCD patients prefer to
receive their medical care in the community setting rather than
having to travel to treatment centers. With Endari and Oncology
Supply's network of community providers, we can provide more SCD
patients with the care they deserve," said Lisa Harrison, President of Oncology Supply. She
added, "Oncology Supply has a large network of Hematology providers
and we are eager to make Endari available to their patients
suffering from SCD."
"We are grateful for this partnership and excited we have
another avenue to increase access for patients we serve,"
remarked George Sekulich, Senior
Vice President of Global Commercialization of Emmaus.
About Endari® (L-glutamine oral
powder)
Indication - Endari is
indicated to reduce the acute complications of sickle cell disease
in adult and pediatric patients five years of age and older.
Important Safety Information - The most common
adverse reactions (incidence >10 percent) in clinical studies
were constipation, nausea, headache, abdominal pain, cough, pain in
extremities, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation included
one case each of hypersplenism, abdominal pain, dyspepsia, burning
sensation, and hot flash.
The safety and efficacy of Endari in sickle cell disease
patients younger than five years of age have not been
established.
For more information, please see full Prescribing Information of
Endari at: www.ENDARIrx.com/PI.
About Oncology Supply
Oncology Supply, based in
Dothan AL, is a trusted partner
and supplier of chemotherapy, immunotherapy and supportive care
products to independent oncology practices nationwide. Driven by a
deep understanding of the vital care community oncologists provide,
Oncology Supply accelerates access to the products and provides the
insights, technology and guidance practices need to maximize
performance and elevate the patient experience.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc.,
is a commercial-stage biopharmaceutical company engaged in the
discovery, development, marketing and sale of innovative treatments
and therapies, including those in the rare and orphan disease
categories. For more information, please
visit www.emmauslifesciences.com.
Company Contacts:
Emmaus Life Sciences, Inc.
Joseph (Jay) C. Sherwood III
Chief Financial Officer
(310) 214-0065 ext. 3005
jsherwood@emmauslifesciences.com
George Sekulich
Senior Vice President of Global Commercialization
(310) 214-0065 ext. 1010
gsekulich@emmauslifesciences.com
Media Contacts:
Russo Partners
David Schull or Caroline Cunningham
(858) 717-2310
david.schull@russopartnersllc.com
caroline.cunningham@russopartnersllc.com
View original
content:http://www.prnewswire.com/news-releases/emmaus-life-sciences-adds-oncology-supply-as-distributor-300908657.html
SOURCE Emmaus Life Sciences